Melanoma cells release small extracellular packages containing the protein nerve growth factor receptor, which primes nearby lymph nodes for tumor metastases, according to a new study by Weill Cornell Medicine investigators.
By mapping all the protein interactions of a dementia-linked protein in the brain called Tau, a team of Weill Cornell Medicine investigators has created a road map for identifying potential new treatment targets for Alzheimer’s disease and related dementia.
A team led by collaborating researchers from Weill Cornell Medicine, Weill Cornell Medicine—Qatar and Qatar Foundation have assembled a large genomic database on the Qatari people, and have used it to develop an advanced but low-cost screening tool for genetic diseases in this highly distinct Middle Eastern population.
Researchers at Weill Cornell Medicine have developed a pre-clinical model of the leading cause of central vision loss in older individuals, called dry age-related macular degeneration (dry AMD), and used it to identify new treatment modalities and drug targets.
In the era of COVID-19 and evolving technology, emergency care providers need to recognize that their care must extend beyond the hospital walls, says Dr. Rahul Sharma, chair of emergency medicine at Weill Cornell Medicine and co-author of a new commentary in NEJM Catalyst.
While the world has celebrated the arrival of highly effective vaccines against COVID-19, new work by researchers at Weill Cornell Medicine and the University of Oxford shows that even unrelated vaccines could help reduce the burden of the pandemic.
Weill Cornell Medicine researchers have received a two-year $500,000 grant from JDRF to evaluate an innovative approach to islet cell transplantation, an experimental treatment for difficult-to-control type 1 diabetes. The research will be conducted in mouse models of this disease.
Aggressive and relatively common lymphomas called diffuse large B cell lymphomas (DLBCLs) have a critical metabolic vulnerability that can be exploited to trick these cancers into starving themselves, according to a study from researchers at Weill Cornell Medicine and Cornell’s Ithaca campus.
COVID-19 vaccination of expectant mothers elicits levels of antibodies to the SARS-CoV-2 outer “spike” protein at the time of delivery that don’t vary dramatically with the timing of vaccination during pregnancy and thus don’t justify delaying vaccination, according to a study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.
The scientists, whose results are published Dec. 23 in Nature, found that a small subset of antibodies elicited by experimental and existing influenza vaccines target a site at the base, or anchor, of the influenza virus hemagglutinin (HA) protein—an “epitope” whose significance was not recognized in prior influenza antibody studies.
Following a sweeping effort in 2019 to address clinical care team well-being across Weill Cornell Medicine, physicians note a reduction in stress and feelings of burnout compared to previous surveys.
Mycobacterium tuberculosis (Mtb), the hardy bacterial species that causes tuberculosis (TB), has an unexpected vulnerability that future drugs may be able to exploit.
Weill Cornell Medicine researchers are using machine learning, a form of artificial intelligence, to shed light on genetic mutations associated with spina bifida.
Depleting copper levels may reduce the production of energy that cancer cells need to travel and establish themselves in other parts of the body by a process referred to as metastasis.
Building on their longtime commitment to social justice, equity and diversity, Louise and Leonard Riggio have made a $5.6 million gift to Weill Cornell Medicine to establish a named scholarship for Black medical students with financial need.
A type of blood thinner may be more effective than aspirin at reducing the risk of recurrent stroke in a subset of stroke patients who experience problems with their hearts’ left ventricle, according to a new study led by Weill Cornell Medicine investigators.
Weill Cornell Medicine has been awarded a nearly $6.5 million, four-year grant from the Department of Defense as part of a multi-institutional Transformative Breast Cancer Consortium.
Investigators at Weill Cornell Medicine have identified significant differences in the molecular characteristics of tumors from younger and older cancer patients across several cancer types.
